BioSpace News Archive

GlycoMantra has been granted worldwide, exclusive rights to a UMB technology to advance the company’s pipeline of therapeutics for treating drug-resistant metastatic colorectal cancer.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that is has shifted its focus for its rapid COVID-19 Neutralizing Antibody (NAb) Test to become For Research Use Only (“RUO”).

Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, proudly announces that Dr. Gerard Blobe, M.D., Ph.D., has joined its Medical Advisory Board.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference.

Varex Imaging Corporation announced the partial redemption of $27 million of its 7.875% senior secured notes due 2027, which represents 10% of the outstanding principal amount of the notes.

Imaging Biometrics, LLC, a subsidiary of IQ-AI Limited, is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.

Nooma Bio, Inc., an innovator in the use of dual-nanopore technology to detect genome-wide structural and epigenetic variation, has announced a new leadership team including DNA sequencing veteran Kevin Corcoran as Chief Executive Officer.

Intertek, a Total Quality Assurance provider to industries worldwide, has issued its first UL 2900-2-1 certification to medical device manufacturer NuVasive, Inc. for Pulse, the company’s integrated technology platform that enables better spine surgeries.

Wave Life Sciences Ltd. (Nasdaq: WVE), today announced the publication of preclinical proof-of-concept data for the company’s novel ADAR-mediated RNA base editing modality in the journal Nature Biotechnology.